Clinical trials: Placebo-Post
Healthy Adult Participants, Asthma Exacerbation
RIG 101 Trial in Healthy Adults and Adults With Asthma
Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy
- Conditions
- Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
- Trial name
- NCT07488897
- Testing
- RIG-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- RIGImmune Inc.
Graft Occlusion, Vascular, Coronary Restenosis
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
This research study is intended to evaluate the safety and effectiveness of 3 different doses of BO-653, an investigational inhibitor of LDL cholesterol oxidation, when given orally twice a day compared to placebo (an inactive…
- Conditions
- Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
- Trial name
- NCT00055510
- Testing
- BO-653
- Where
- 29 sites in United States
- Sponsor
- Chugai Pharma USA
Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
In this clinical trial, participants with nerve pain after shingles or nerve injury will receive injections with NT 201 or placebo. The purpose is to measure the decrease of nerve pain with NT 201 compared to placebo.
- Trial name
- PaiNT (NCT06091020)
- Testing
- IncobotulinumtoxinA
- Where
- 31 sites in Bulgaria, France and 4 more
- Volunteers
- 123 people
- Sponsor
- Merz Therapeutics GmbH
Fracture Healing
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
- Trial name
- STARTT (NCT00907296)
- Testing
- Romosozumab
- Where
- 103 sites in United States, Australia and 21 more
- Volunteers
- 402 people
- Sponsor
- Amgen
Delayed Graft Function
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
- Trial name
- ReGIFT (NCT02610296)
- Testing
- QPI-1002
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 594 people
- Sponsor
- Quark Pharmaceuticals
Post Bariatric Hypoglycemia
Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB).
- Trial name
- LUCIDITY (NCT06747468)
- Testing
- Avexitide
- Where
- 21 sites in United States
- Volunteers
- 75 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Dermatitis, Atopic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive
This study is divided into two parts: Part A of the study is double blinded, randomized, placebo-controlled and aims to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamic (PD) effect of a single…
- Trial name
- NCT05590338
- Testing
- GSK1070806
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non Squamous Non Small Cell Lung
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination…
- Trial name
- NCT02766140
- Testing
- SHR1020 plus Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.
Postbariatric Hypoglycemia
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
- Trial name
- EMERGE (NCT07760961)
- Testing
- Mizagliflozin 5 mg, Mizagliflozin 10 mg
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vogenx, Inc.
Lupus Nephritis
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the…
- Trial name
- NCT02770170
- Testing
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
CHF6297 is a potent and selective inhibitor of human MAP kinase p38 being developed as an anti-inflammatory agent for the treatment of inflammatory airways diseases.
- Trial name
- CHF6297 FIH (NCT02815488)
- Testing
- CHF6297 (Part 1 - SAD), CHF6297 (Part 2 - MAD), CHF6297 (Part 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Delayed Graft Function
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
- Trial name
- NCT02145182
- Testing
- Eculizumab
- Where
- 78 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy
Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components
This Phase I trial in healthy, post-menopausal women is designed as a double-blind, placebo-controlled, randomized, ascending single-dose safety trial.
- Trial name
- NCT00453297
- Testing
- MF101
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bionovo
Dyslipidemia
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects
- Trial name
- NCT01879020
- Testing
- TA-8995
- Where
- Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Hydration, Blood Glucose
Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise
Although the general effectiveness of carbohydrate/electrolyte-based functional sports drinks on rehydration, recovery and sports performance has been widely demonstrated, there is controversy about the amounts, proportions and…
- Conditions
- Hydration, Blood Glucose, Sport Recovery, Microbiota
- Trial name
- NCT05352724
- Testing
- Hydration drink
- Where
- Spain
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Bioithas SL
Diabetes Mellitus, Type 2
A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of AP026 (TQA2226) for injection in adult healthy subjects, which planned to recruit 74 healthy subjects.
- Trial name
- NCT06143423
- Testing
- AP026 (TQA2226) for injection
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Healthy Male
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
This is a two part study. Part A will determine the maximum tolerated dose of TC-5214 administered to healthy male subjects in single ascending oral doses.
- Trial name
- NCT01359618
- Testing
- TC-5214, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-ST Elevation Myocardial Infarction (NSTEMI)
Prevention of Acute Kidney Injury in Patients With NSTEMI
A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography.
- Trial name
- AKI (NCT04912141)
- Where
- 4 sites in Switzerland
- Volunteers
- 29 people
- Sponsor
- Pharming Technologies B.V.
Type 1 Diabetes, Diabetes Mellitus
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
The purpose of this study is to assess safety and tolerability and determine the pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of CBX129801 (long-acting synthetic C-peptide) in type 1…
- Conditions
- Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
- Trial name
- NCT01293461
- Testing
- CBX129801
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cebix Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.